- NHS staff in the UK are reportedly boycotting Palantir's Federated Data Platform due to ethical concerns linked to the company's US defense work and leadership.
- The pushback focuses on trust, data use, and corporate values within the public health system.
- This reaction could affect how Palantir Technologies (NasdaqGS:PLTR) is viewed in current and future government healthcare contracts.
For investors watching Palantir Technologies, the ethical controversy around its NHS work comes at a time when the stock trades at $147.93 and has seen very large gains over three years and five years. The share price is up 90.0% over the past year. Year to date the stock shows an 11.9% decline and a 5.9% decline over the past month, with a 7.5% gain over the past week.
This boycott debate adds a new layer of reputational and operational risk for a company that often pitches itself as a trusted data partner for governments. Readers may want to watch how UK policymakers, hospital trusts, and clinicians respond to these concerns, as any changes in adoption, contract scope, or governance could influence how Palantir approaches future healthcare deals in other markets.
Stay updated on the most important news stories for Palantir Technologies by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Palantir Technologies.
We've flagged 0 risks for Palantir Technologies. See which could impact your investment.
Quick Assessment
- ⚖️ Price vs Analyst Target: At US$147.93, Palantir trades about 20% below the US$185.25 analyst target, with forecasts ranging widely from US$70 to US$260.
- ❌ Simply Wall St Valuation: Shares are trading 19.3% above Simply Wall St's estimated fair value, which flags an overvaluation signal.
- ❌ Recent Momentum: The 30 day return is a 5.9% decline, suggesting recent weakness despite strong longer term gains.
There is only one way to know the right time to buy, sell or hold Palantir Technologies: head to Simply Wall St's company report for the latest analysis of Palantir Technologies's Fair Value.
Key Considerations
- 📊 The NHS boycott story directly challenges Palantir's positioning as a trusted public sector partner, which could influence sentiment on its government focused revenue streams.
- 📊 Watch any updates on UK contract scope, clinician adoption, and governance terms, alongside the current rich 217.7x P/E and revenue and earnings growth figures.
- ⚠️ The key risk is that ethical concerns spread to other customers or regions, which could affect future deal flow even though no formal risk flags are currently recorded.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Palantir Technologies analysis. Alternatively, you can check out the community page for Palantir Technologies to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com